Opella in the news

Consumer healthcare brands are increasingly adopting FMCG-like media strategies, focusing on digital channels and brand building, to meet changing consumer demands and market dynamics.

Sanofi, UCB, and Opella are collaborating in the Clean Heat Program to decarbonize industrial heat across their pharmaceutical supply chains.

Sanofi, UCB, and Opella have joined the Clean Heat Program to reduce carbon emissions from industrial heating in their manufacturing facilities, supported by Secaro and ERM.

Sanofi, UCB, and Opella joined the Clean Heat Programme with AstraZeneca to decarbonize industrial heating in their supply chains.

Pharmaceutical companies Sanofi, UCB, and Opella have joined AstraZeneca in the Clean Heat Program to decarbonize industrial heating in the pharma supply chain.

Sanofi, UCB, and Opella joined the Clean Heat Program to reduce industrial emissions by switching to low-carbon heating alternatives.

Opella's General Manager for Africa, the Middle East, and Turkey discusses the company's strategy to capitalize on the region's shift towards preventive healthcare and consumer empowerment by strengthening self-care solutions and sustainability initiatives.

Opella implemented Candex to streamline tail spend management and enhance its procurement function, aiming for a simplified buying experience for business users.

Opella and Hoan My Academy partnered to advance medical education and public health awareness in Vietnam.

Opella's procurement leader, Lyvio Frimat, advocates for a strategic approach to AI adoption, emphasizing fixing core processes and integrating human expertise rather than simply overlaying technology on broken systems.

Opella is addressing consumer health literacy issues by simplifying product information and collaborating with pharmacists to empower better self-care decisions amidst information overload.

Opella leverages Vietnam as its sole Asian R&D center and AMEA Innovation Week host, signifying the country's evolving role beyond manufacturing.

Opella begins a new phase as an independent leader in consumer health, based in Chattanooga.

The Delhi High Court restrained Pureca Laboratories from using the PHENSERYL mark, citing deceptive similarity to Opella Healthcare's PHENSEDYL trademark and packaging.

Karan Bhatia exited Opella after nine years to join Asahi Group Holdings as Director, AGPS, having been instrumental in building Opella's global business services and capability centers.

Opella invested $70 million in a new Enterogermina production line in Mexico, increasing capacity and strengthening its regional manufacturing network.

Opella appointed Radu Stănescu as Country Head for Romania & Moldova, bringing commercial leadership experience to drive growth and operational excellence.

Opella invested MX$1.2 billion to open a new Enterogermina production line in Mexico, increasing capacity and local manufacturing for domestic and Latin American markets.

Opella transferred Enterogermina production to its Mexico plant with a US$70 million investment, expanding capacity and making it a global manufacturing hub.

Opella expanded its Enterogermina production in Mexico with a MX$1.2 billion investment, boosting capacity by 200 million units and increasing local manufacturing for the domestic and Latin American markets.